Three Independent Investment Opportunities
A clinical-stage antiviral dermatology program with immediate commercial revenue, a structured ophthalmic immunomodulation asset, and a disruptive portable medical device for the global dialysis market.
Request Confidential Investment DeckInvestment Assets
ErpeCream®
Antiviral Dermatology · Phase IIb ongoing
- Phase IIb head-to-head vs acyclovir (PPD, ref. BC147404-01)
- Consumer revenue: Active in EU, Gulf, Latam
- 36-month stability incl. ICH Zone 4B
ACRO-EYE™
Ophthalmic Immunomodulation · Phase III design complete
- Galenic use established. Phase III protocol designed with PPD
- Market signal: 2–3 major pharma companies in preliminary acquisition discussions
- No direct equivalent in galenic ophthalmic market
Easy-Dialysis™
Nephrology MedTech · Portable hemodialysis
- Prototype completed. Multiple partner discussions ongoing
- Global dialysis market >€90B annually
- No dominant portable solution exists
Investment Thesis
Revenue today, proven efficacy, defensible IP, Phase IIb value inflection.
Revenue Today, Not Just Tomorrow
ErpeCream® and ErpeLips™ are registered consumer products already generating commercial revenue in EU, Gulf, and Latam markets.
Phase IIb Creates Hard Value Inflection
Phase IIb study (80 patients, head-to-head vs acyclovir, PPD/Thermo Fisher) produces primary readout 7–8 months from start (May 2026). That readout triggers licensing.
IP-Protected, No Generic Risk
Nanoemulsion formulation patent-protected in EU and US. 36-month validated stability (ICH Zone 4B) expands commercial footprint significantly.
Market Size
Exit Options
Phase IIb Co-Investment
Participation in study financing. Structured return on licensing post-readout.
Licensing Post-IIb
Direct acquisition of regional or global rights post-readout. IP + clinical data + regulatory package.
Phase III Co-Development
Partnership on full pivotal program. 420 patients, EMA/FDA aligned.
Strategic Acquisition
Acquisition of entire asset or company. Data room available under NDA.
Request Confidential Investment Deck
We respond within 48 hours. A mutual NDA can be provided for access to the full data room.